![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Tuesday, September 01, 2020 9:15:37 AM
"All three Brilacidin treatment arms (two single-dose regimens and one three-day dose regimen) reached the primary endpoint, with the clinical success rate for each dosing regimen statistically comparable to the clinical success rate of the FDA-approved seven-day dosing regimen of daptomycin. All Brilacidin treatment regimens were well tolerated. There were six severe adverse events (SAE) reported across the study, none of which were considered related to Brilacidin by the principal investigator".
http://www.ipharminc.com/press-release/2016/11/16/cellceutix-announces-positive-top-line-data-from-phase-2b-absssi-trial-single-dose-brilacidin-comparable-to-7-days-of-daptomycin
•Phase 1 studies completed•Ascending single-dose (PMX63-101), multiple-dose x 5 days (PMX63-102), and fixed-dose x 14 days (PMX63-103)•IV infusions q48H, q24H, and q12H•Pharmacokinetics•Consistent and linear pharmacokinetics in plasma with half-life of ~ 15-23 hours. •Ex-vivo efficacy•Long lasting bactericidal and inhibitory activity vs. MSSA and MRSA in serum from human subjects after doses as low as 0.1 mg/kg •Safety•Mild paraesthesiaand hypoaesthesia(numbness and tingling) with acute onset and rapid resolution No neurotoxicity evident in human subjects or animal safety studies•Transient blood pressure elevation •Dose-dependent; reversible after treatment discontinuation•Phase 2 in ABSSSI •Brilacidindosed in > 300 patients•Effective; Generally safe and well-tolerated•Phase 2a data presented at ICAAC, 2012•PK/PD data presented at ECCMID, 2013•Phase 2b data presented atECCMID, 2015
https://static1.squarespace.com/static/5715352e20c647639137f992/t/583f8286d2b85731b8713a36/1480557192947/A-Randomized-Double-Blind-Study-Comparing-Single-Dose-and-Short-Course-Brilacidin-to-Daptomycin-in-the-Treatment-of-Acute-Bacterial-Skin-Skin-Structure-Infections-ABSSSI1.pdf
•Single-dose brilacidinwas safe and well tolerated in a phase 2b ABSSSI study•Reduction in total dose decreases the frequency, severity, and duration of adverse events, vs. phase 2a study•Blood pressure events low in 0.6 mg/kg single-dose regimen, similar to or better than daptomycin(active control)•There were no treatment-related SAEs or hypertension-related SAEs•Numbness/Tingling mild, transient, and decreased in frequency and severity, vs. phase 2a study•PK/PD model correctly predicted decrease in AEs with lower total dose, particularly low single-dose regimens
https://investorshub.advfn.com/secure/post_reply.aspx?message_id=158016861
As I mentioned IPIX has reported covid19 is responsive to Brilacidin at a lower dose which would further reduce the paresthesias
GLTA Farrell
Recent IPIX News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 01:30:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/05/2023 09:25:58 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 09:05:44 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/15/2023 01:00:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2023 08:15:25 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/28/2023 01:00:08 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM
Branded Legacy, Inc. and Hemp Emu Announce Strategic Partnership to Enhance CBD Product Manufacturing • BLEG • Jun 27, 2024 8:30 AM
POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • POET • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM